Effect of teriparatide (rh-PTH 1–34) versus bisphosphonate on the healing of osteoporotic vertebral compression fracture: A retrospective comparative study

Table 1 Demographic data for the teriparatide group versus the bisphosphonate group

	TPD (n = 38)	BP (n = 60)	p-value
Age (years) (mean ± SD)	75.5 ± 7.1	77.6 ± 8.0	0.205
Gender (male:female)	4:34	8:52	0.761
BMD at lumbar spine (g/cm²) (mean ± SD)	0.709 ± 0.020	0.692 ± 0.019	0.561
BMD at femoral neck (g/cm²) (mean ± SD)	0.520 ± 0.018	0.531 ± 0.015	0.655
GFR (mL/min/1.73²)	64.0 ± 3.2	65.1 ± 2.8	0.796
Pre-existing VCF (present: not present)	8:30	15:45	0.653
Level of vertebral fracture (non-TL:TL)	17:21	18:42	0.138
Posterior wall fracture (not injured:injured)	16:22	28:32	0.658
Prior bisphosphonate use (not used:used)	17:21	42:18	0.021*

*p < 0.05, TPD teriparatide group, BP bisphosphonate group, SD standard deviation, BMD bone mineral density, GFR glomerular filtration rate, VCF vertebral compression fracture, TL thoracolumbar spine (T11-L2), non-TL non-thoracolumbar spine (T5-T10 or L3-L5)

ISSN: 1471-2474